[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346049-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346049-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","vascular-and-mesenchymal-signatures-of-breast-cancers-associated-with-yo-and-ri-paraneoplastic-syndrome","Vascular and mesenchymal signatures of breast cancers associated with Yo and Ri paraneoplastic syndrome","","Paraneoplastic neurological syndromes (PNSs) are rare autoimmune disorders arising in the setting of cancer, yet the mechanisms behind loss of immune tolerance remain unclear. Breast cancers linked to Yo-PNS and Ri-PNS exhibit distinct immune and genetic features, implying tumor-intrinsic drivers. This study tests whether PNS-associated breast cancers also show additional, previously unassessed stromal and vascular signatures using transcriptomic profiling and immunohistochemistry.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/vascular-and-mesenchymal-signatures-of-breast-cancers-associated-with-yo-and-ri-paraneoplastic-syndrome/346049/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/vascular-and-mesenchymal-signatures-of-breast-cancers-associated-with-yo-and-ri-paraneoplastic-syndrome/346049.png","ImageObject",300,407,{"name":42,"@type":43},"Genevieve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the study’s main objective?","Question",{"text":63,"@type":64},"To determine whether Yo-PNS– and Ri-PNS–associated breast cancers show additional, stromal and vascular features beyond known immune and genetic differences.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the breast cancer groups compared in this research?",{"text":68,"@type":64},"Twelve Yo-PNS–associated breast cancers and ten Ri-PNS–associated breast cancers were compared with two independent non-PNS control cohorts using a targeted 760-gene transcriptomic panel and immunohistochemistry.",{"name":70,"@type":61,"acceptedAnswer":71},"What vascular or stromal signatures were identified?",{"text":72,"@type":64},"Transcriptomic analysis highlighted common differentially expressed genes, including FLT4 upregulation, while immunohistochemistry confirmed increased podoplanin-positive lymphatic structures; Yo-BCs additionally showed a predominant mesenchymal phenotype and hypoxia-related gene downregulation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346049,1790591511,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Nicola etal. Breast Cancer Research (2026) 28:148 Breast Cancer Research  \n[https://doi.org/10.1186/s13058-026-02321-9](https://doi.org/10.1186/s13058-026-02321-9)  \nRESEARCH Open Access  \nVascular and mesenchymal signatures of breast cancers associated with Yo and Ri  \nparaneoplastic syndrome  \nCeleste Nicola1,2,3, Elise Peter1,2,3, Macarena Villagran-Garcia1,2,3, Isabelle Treilleux4, Géraldine Picard2, Véronique Rogemond1,2, Marine Villard2, Jonathan Lopez3, Bastien Joubert1,2,3, Jérôme Honnorat1,2,3, Valentin Wucher1,2,3 and Virginie Desestret1,2,3*  \nAbstract  \nBackground Paraneoplastic neurological syndromes (PNSs) are rare autoimmune diseases that occur in the context of cancer, but the mechanisms leading to immune tolerance breakdown remain unknown. Breast cancers (BCs) associated with Yo-PNS and Ri-PNS show distinct immune and genetic specificities, suggesting that tumour characteristics may contribute to autoimmunity. Herein, we aimed to investigate whether PNS-associated BCs display additional specificities, including stromal and vascular features that have not been systematically assessed.  \nMethods We compared 12 BCs associated with Yo-PNS (Yo-BCs) and 10 BCs associated with Ri-PNS (Ri-BCs) with two independent cohorts of non-PNS breast cancer controls (CtrlYo and CtrlRi) using tumour transcriptomic profiling with a targeted 760-gene panel and complementary immunohistochemistry.  \nResults Transcriptomic analysis identified 27 genes commonly differentially expressed inYo-BCs and Ri-BCs compared with their respective controls, including upregulation of FLT4 . Immunohistochemistry confirmed increased podoplanin-positive lymphatic structures in both Yo-BCs and Ri-BCs. In parallel, Yo-BCs showed predominant mesenchymal phenotype and downregulation of genes associated with hypoxia (HIF1A, FLT1, LDHA, P4HA2)  \ncompared with CtrlYo. These features were not present in Ri-BCs when compared with CtrlRi.  \nConclusion These findings not only highlight subtype-specificities of Yo-and Ri-associated BCs, but also identify lymphangiogenesis as a shared tumour-intrinsic feature that may be part of a cancer-specific context required to initiate or sustain autoimmunity in PNS.  \nKeywords Paraneoplastic neurological syndrome, Lymphangiogenesis, Lymph node metastasis  \n*Correspondence:  \nVirginie Desestret  \n[virginie.desestret@chu-lyon.fr](virginie.desestret@chu-lyon.fr)  \n1Synaptopathies and Autoantibodies (SynatAc) Team, Institut NeuroMyoGène-MeLis, INSERM U1314/CNRS UMR 5284, Université de Lyon, Lyon, France  \n2French Reference Center On Paraneoplastic Neurological Syndromes, Hospices Civils de Lyon, Lyon, France  \n3Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France 4Department of Biopathology, Centre Léon Bérard, Lyon, France  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses/by/4.0/.)  \nNicola et al. Breast Cancer Research (2026) 28:148  \nBackground  \nParaneoplastic neurological syndromes (PNSs) are rare autoimmune complications associated with cancer. They are characterised by an immune response directed against neuronal ","cbCaib9uK614nt4q","https://ap.wps.com/l/cbCaib9uK614nt4q","pdf",2025052,11,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Background\n## Clinical and immunological context\n## Study rationale","[{\"question\":\"What is the study’s main objective?\",\"answer\":\"To determine whether Yo-PNS– and Ri-PNS–associated breast cancers show additional, stromal and vascular features beyond known immune and genetic differences.\"},{\"question\":\"How were the breast cancer groups compared in this research?\",\"answer\":\"Twelve Yo-PNS–associated breast cancers and ten Ri-PNS–associated breast cancers were compared with two independent non-PNS control cohorts using a targeted 760-gene transcriptomic panel and immunohistochemistry.\"},{\"question\":\"What vascular or stromal signatures were identified?\",\"answer\":\"Transcriptomic analysis highlighted common differentially expressed genes, including FLT4 upregulation, while immunohistochemistry confirmed increased podoplanin-positive lymphatic structures; Yo-BCs additionally showed a predominant mesenchymal phenotype and hypoxia-related gene downregulation.\"}]","Vascular and mesenchymal signatures of breast cancers associated with Yo and Ri paraneoplastic syndrome | PDF",1790059857,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d34680725892ecd3975ac3dab84fafd.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bf56d649dd948b431e700b119d6084e6.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/51f9d2afa4e685cf1582c6480788e7c8.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/17647b9a71e41bbcabd4278994ab0f5a.webp",980,1306]